Abstract Number: 628 • 2016 ACR/ARHP Annual Meeting
Analysis of Baseline Characteristics of Rheumatoid Arthritis Patients Treated with Abatacept Compared to Those Treated with Tumor Necrosis Factor Inhibitors in Clinical Practice
Background/Purpose: Currently, the most widely used biological agents for rheumatoid arthritis (RA) patients are the inhibitors of the tumor necrosis factor (TNFi), although other biological…Abstract Number: 629 • 2016 ACR/ARHP Annual Meeting
Golimumab Improves Patient-Reported Outcomes and Socio- and Health-Economic Parameters in Patients with Rheumatoid Arthritis (RA), Psoriatic Arthritis (PsA), and Ankylosing Spondylitis (AS): Results from a Non-Interventional Clinical Evaluation in Germany
Background/Purpose: Golimumab (GLM) has shown its efficacy and safety in various randomized clinical trials with patients eligible for clinical studies. Data from patient-reported outcomes (PROs)…Abstract Number: 647 • 2016 ACR/ARHP Annual Meeting
Genomic and Epigenetic Bioinformatics Demonstrate Dual TNF-α and IL17A Target Engagement By ABT-122, and Suggest Mainly TNF-α–Mediated Relative Target Contribution to Drug Response in MTX-IR Rheumatoid Arthritis Patients
Background/Purpose: ABT-122 is a dual variable domain (DVD-Ig) biologic which inhibits TNF-α and IL17A. In a 12-wk phase 2 study (NCT02141997) in MTX-IR patients (pts)…Abstract Number: 650 • 2016 ACR/ARHP Annual Meeting
ABT-122, a Tnf– and IL-17–Targeted Dual Variable Domain (DVD)–Ig™ in Rheumatoid Arthritis Patients with Inadequate Response to Methotrexate: Results from a Phase 2 Trial
Background/Purpose: Tumor necrosis factor (TNF) and interleukin 17 (IL-17) appear to independently contribute to the pathophysiology of rheumatoid arthritis (RA), synergistically inducing inflammatory mediators leading…Abstract Number: 652 • 2016 ACR/ARHP Annual Meeting
The Reasons for Discontinuation of Combination Therapy with Methotrexate and Tumor Necrosis Factor Inhibitors Versus Triple Therapy Differ Significantly Because of Higher Adverse Events with Triple Therapy
Background/Purpose: We recently reported that real-world persistence in Veteran’s Affairs (VA) patients was lower in Rheumatoid arthritis (RA) patients receiving triple therapy [methotrexate (MTX), sulfasalazine…Abstract Number: 921 • 2016 ACR/ARHP Annual Meeting
The Anti-IL-17A Antibody Secukinumab (Cosentyx®, AIN457) Diminishes the Expression of the NFκB Pathway Modulator Iκbζ
Background/Purpose: In order to better understand the IL-17A signaling pathway we have analyzed the effects of IL-17A in human primary synovial fibroblasts (SF), a…Abstract Number: 1568 • 2016 ACR/ARHP Annual Meeting
Microrna-17 Suppresses TNF-α Signaling By Reducing TRAF2 and cIAP2 Association in Rheumatoid Arthritis Synovial Fibroblasts
Background/Purpose: TNF-α is a major cytokine implicated in rheumatoid arthritis (RA) and its expression has shown to be regulated at transcriptional and posttranscriptional levels.…Abstract Number: 2155 • 2016 ACR/ARHP Annual Meeting
Crosstalk Between IL-6 and TNF-Alpha Signaling Pathway in Rheumatoid Arthritis Synovial Fibroblasts
Background/Purpose: Although elevated IL-6 and its soluble receptor (sIL6R) have been found in the serum and synovium of arthritic patients, the molecular mechanisms by which…Abstract Number: 2533 • 2016 ACR/ARHP Annual Meeting
Are There Differences in Baseline Comorbidities Between Rheumatoid Arthritis Patients Treated with Abatacept and Those Treated with Tumor Necrosis Factor Inhibitors?
Background/Purpose: Rheumatoid arthritis (RA) patients frequently report concomitant comorbidities that could worsen their prognosis. Tumor necrosis factor inhibitors (TNFi), the most common biological agents used,…Abstract Number: 2651 • 2016 ACR/ARHP Annual Meeting
Predictors of Inadequate Response and Rapid Radiographic Progression in Patients with Early Rheumatoid Arthritis Receiving Methotrexate: a Post Hoc Analysis of 2 Randomized, Controlled Trials of Adalimumab
Background/Purpose: Methotrexate (MTX) is recommended as first-line therapy in patients (pts) with rheumatoid arthritis (RA).1 However, information is limited regarding factors that may predict a…Abstract Number: 3012 • 2016 ACR/ARHP Annual Meeting
Clinical Predictors of TNF-Inhibitor Free Disease Control in Patients with Rheumatoid Arthritis after Stopping TNFi Treatment: Results from a Dutch Multicentre Pragmatic Open-Label Randomized Controlled Trial.
Background/Purpose: Tumor Necrosis Factor inhibitor (TNFi) free prolonged acceptable disease control in patients with rheumatoid arthritis (RA), in stable remission or low disease activity…Abstract Number: 3220 • 2016 ACR/ARHP Annual Meeting
Distinct Single Cell Gene Expression Signatures of Monocyte Subsets Differentiate Between TNF-Alpha Inhibitor Treatment Response Groups in Rheumatoid Arthritis
Background/Purpose: In rheumatoid arthritis (RA), initiating effective treatment as soon as possible within the so-called therapeutic “window of opportunity” is the strategy, and remission is…Abstract Number: 2594 • 2015 ACR/ARHP Annual Meeting
Multi-Biomarker Disease Activity Score As a Predictor of Flare in Patients with Rheumatoid Arthritis Who Stop TNF-Alpha-Inhibitor Therapy
Background/Purpose: Prediction which rheumatoid arthritis (RA) patients in low disease activity (LDA) can successfully discontinue TNF inhibition (TNFi) may improve the cost-effectiveness of RA management.…Abstract Number: 3170 • 2015 ACR/ARHP Annual Meeting
Peripheral Osteoblastogenesis in Rheumatoid Arthritis Is Enhanced after TNF Blocker Treatment, Irrespective of Systemic Inflammation
Background/Purpose: We investigated osteoclastogenesis and osteoblastogenesis in peripheral blood before and 6 months after TNF blocker treatment in seropositive RA patients. Methods: Seventeen seropositive…Abstract Number: 910 • 2015 ACR/ARHP Annual Meeting
Tumor Necrosis Factor-Alpha Inhibitor Use and the Risk of Incident Hypertension in Patients with Rheumatoid Arthritis: A Retrospective Cohort Study
Background/Purpose: Results from several small studies support the potential blood pressure lowering effect of tumor necrosis factor (TNF)-a inhibitors in rheumatoid arthritis (RA) patients. Yet,…
ACR Meeting Abstracts